Department of Cardiology, The First Affiliated Hospital, Xinxiang Medical University, Weihui, China.
Henan Key Laboratory of Medical Tissue Regeneration, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003, China.
Cardiovasc Drugs Ther. 2023 Jun;37(3):571-584. doi: 10.1007/s10557-022-07362-8. Epub 2022 Jul 7.
Cardiovascular diseases (CVDs) are the leading cause of death globally. Atherosclerosis is the basis of major CVDs - myocardial ischemia, heart failure, and stroke. Among numerous functional molecules, the transcription factor nuclear factor κB (NF-κB) has been linked to downstream target genes involved in atherosclerosis. The activation of the NF-κB family and its downstream target genes in response to environmental and cellular stress, hypoxia, and ischemia initiate different pathological events such as innate and adaptive immunity, and cell survival, differentiation, and proliferation. Thus, NF-κB is a potential therapeutic target in the treatment of atherosclerosis and related CVDs. Several biologics and small molecules as well as peptide/proteins have been shown to regulate NF-κB dependent signaling pathways. In this review, we will focus on the function of NF-κB in CVDs and the role of NF-κB inhibitors in the treatment of CVDs.
心血管疾病（CVDs）是全球范围内的主要致死原因。动脉粥样硬化是大多数 CVDs（如心肌缺血、心力衰竭和中风）的基础。在众多功能分子中，转录因子核因子κB（NF-κB）与涉及动脉粥样硬化的下游靶基因有关。NF-κB 家族及其下游靶基因的激活，可响应环境和细胞应激、缺氧和缺血，启动不同的病理事件，如先天和适应性免疫、细胞存活、分化和增殖。因此，NF-κB 是治疗动脉粥样硬化和相关 CVDs 的潜在治疗靶点。已有多种生物制剂和小分子以及肽/蛋白被证明可以调节 NF-κB 依赖性信号通路。在本综述中，我们将重点关注 NF-κB 在 CVDs 中的功能以及 NF-κB 抑制剂在 CVDs 治疗中的作用。
